Suitability depends on the condition, cell type, plans permitted under Korean law, and an individual assessment. The EHL team reviews your health information and explains the available options before confirming a care plan.
EHL BIO publishes its main programmes on its research pages: ADSTEM Inj. for moderate to severe atopic dermatitis, which the hospital's affiliated research centre states completed Phase 1 in 2017, completed Phase 2 in 2023 and had a Phase 3 IND submitted in 2024; KDSTEM Inj. for chronic kidney disease, using autologous urine-derived stem cells, with IND approval and Phase 1 initiation stated for 2023; RASTEM Inj. for rheumatoid arthritis, where the hospital's affiliated research centre states non-clinical work is being completed and a clinical trial is in preparation; and PDSTEM Inj. for Parkinson's disease, stated to be at non-clinical stage. The institution also describes Keycell-IM immune cell work and adipose-derived exosome research listing indications under study such as neuropathic pain, cartilage regeneration, wound healing, hypertension, retinopathy and diabetes. Readers should keep one distinction clear: research status is not approval to treat. Phase 1 targets safety, Phase 2 assesses dose and signals of effect, and only Phase 3 with large numbers can support efficacy conclusions. Korean regulatory status also does not mean Thailand permits the same treatment.
Source: EHL BIO (research pages)
Related disease topics
Experts behind this content
EHL Thailand Medical Information Team — Evidence levels, regulatory status, and separating hospital information from medical information
EHL BIO scientific information is compiled alongside public information from its research team and GMP centre. See the full expert panel